Lawrenceville, New Jersey – August 26, 2026
IMUNON announced plans to host its 2026 R&D Day on September 23 in New York City, focusing on the company’s lead oncology program, IMNN-001, and its ongoing Phase 3 OVATION 3 trial in newly diagnosed advanced ovarian cancer. The event will bring together company management and leading oncology experts to discuss the clinical development of IMNN-001, supporting scientific data and upcoming milestones for the pivotal study. IMUNON said the R&D Day will provide investors, analysts and media with a detailed update on the company’s development strategy for its DNA-mediated IL-12 immunotherapy. The program will also include discussion of the company’s Phase 2 minimal residual disease study conducted with Break Through Cancer and researchers at The University of Texas MD Anderson Cancer Center. A patient previously treated with IMNN-001 is also expected to share her experience from the clinical trial. The event will be held at the Sofitel New York, beginning at 10:00 a.m. ET, with a live webcast available for virtual participants.
OVATION 3 Takes Center Stage in Phase 3 Development
The primary focus of the R&D Day will be the ongoing Phase 3 OVATION 3 clinical trial, which is evaluating IMNN-001 in women with newly diagnosed advanced ovarian cancer. The company plans to provide updates on clinical progress, supporting scientific evidence and upcoming development milestones. OVATION 3 follows earlier clinical development of IMNN-001, including the Phase 1b OVATION 1 study and the Phase 2 OVATION 2 study. In OVATION 2, IMUNON evaluated IMNN-001 administered intraperitoneally in combination with neoadjuvant and adjuvant paclitaxel and carboplatin compared with standard-of-care chemotherapy alone in 112 patients with newly diagnosed advanced ovarian cancer. The company previously reported positive results from the Phase 2 study, providing the clinical foundation for continued development in the Phase 3 setting. The upcoming R&D Day is intended to provide a broader view of the OVATION 3 program, including its scientific rationale, clinical progress and planned milestones. However, the event announcement does not provide new Phase 3 efficacy results, so the principal near-term value of the event will be additional clinical and development updates rather than a new efficacy readout.
IMNN-001 Uses Localized IL-12 Immunotherapy
IMNN-001 is being developed using IMUNON’s proprietary TheraPlas platform, which uses a DNA plasmid containing the IL-12 gene within a nanoparticle delivery system. The approach is designed to enable cells at the treatment site to produce IL-12 locally and persistently. IL-12 is an important cytokine involved in stimulating anti-tumor immune activity, including the proliferation and activation of T lymphocytes and natural killer cells. IMUNON is developing the therapy as a localized immunotherapy for advanced ovarian cancer, with intraperitoneal administration intended to deliver the treatment directly to the tumor-associated environment. Earlier studies evaluated IMNN-001 both as monotherapy and in combination with chemotherapy in patients with ovarian cancer, while the OVATION program has progressively moved the candidate toward earlier-stage disease and larger clinical studies. The company has also evaluated IMNN-001 in a Phase 2 MRD study, expanding investigation of its potential role in ovarian cancer beyond the pivotal program. The R&D Day will provide an opportunity for the company and external experts to discuss the underlying science and clinical development of this DNA-based cancer immunotherapy.
Advertisement
IMUNON Prepares for Next Development Milestones
The September R&D Day represents an important clinical-development communication milestone for IMUNON as the company advances IMNN-001 through Phase 3 testing. Presentations from oncology specialists and company leadership are expected to address the scientific basis of the program, clinical progress in OVATION 3 and future development plans. The inclusion of insights from a patient treated with IMNN-001 will also provide a patient perspective alongside the scientific and clinical presentations. IMUNON is developing TheraPlas as a non-viral DNA-based platform intended to produce therapeutic proteins locally, with its initial focus on cytokine-based cancer treatment. Beyond IMNN-001, the company has completed dosing in a first-in-human study of its investigational prophylactic vaccine IMNN-101. For the ovarian cancer program, however, the key focus remains the successful execution of OVATION 3 and the generation of evidence needed to determine the future role of IMNN-001 in advanced ovarian cancer. The upcoming R&D Day is expected to provide additional visibility into the program’s progress and the company’s next clinical milestones.
Source:IMUNON press relese
